High Ki67 expression is associated with a survivaldisadvantage in patients with ER+/HER2– breast cancer,indicating that these patients might have a higher risk ofrecurrence after primary treatment and might therefore benefitfrom individualized treatment. This evidence concerns the gene MKI67 and breast carcinoma.